ESPR - Esperion Therapeutics, Inc.
IEX Last Trade
2.305
0.020 0.868%
Share volume: 64,227
Last Updated: Thu 26 Dec 2024 08:29:58 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$2.28
0.02
0.88%
Fundamental analysis
35%
Profitability
30%
Dept financing
35%
Liquidity
75%
Performance
30%
Performance
5 Days
2.68%
1 Month
-10.51%
3 Months
40.24%
6 Months
5.50%
1 Year
-10.85%
2 Year
-60.82%
Key data
Stock price
$2.30
DAY RANGE
$2.16 - $2.30
52 WEEK RANGE
$1.67 - $3.94
52 WEEK CHANGE
-$25.32
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Sheldon L. Koenig
Region: US
Website: esperion.com
Employees: 200
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: esperion.com
Employees: 200
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Esperion Therapeutics, Inc. develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program.
Recent news